Form 4: LivaNova Executive's Routine Share Activity Post-RSU Vesting
Statement of Changes in Beneficial Ownership
LivaNova PLC's President of Cardiopulmonary, Franco Poletti, reported routine share transactions related to RSU vesting and tax obligations.
Summary
- Franco Poletti, President of Cardiopulmonary at LivaNova PLC, reported transactions on March 30, 2026, related to his beneficial ownership.
- Poletti acquired 3,184 ordinary shares through the settlement of vested Restricted Stock Units (RSUs) at a price of $0.
- Concurrently, 1,370 ordinary shares were disposed of at a price of $61.27 to satisfy tax liabilities associated with the RSU vesting.
- Following these transactions, Poletti's direct beneficial ownership of ordinary shares is 10,755, down from 12,125 prior to the reported transactions.
- Indirect beneficial ownership remains at 219 shares held by a spouse.
- The filing details the vesting of several RSU grants from 2022, 2023, 2024, and 2025, with the 2025 grant having its first vesting installment on the transaction date.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine executive compensation event involving RSU vesting and subsequent tax-related share disposition, which typically has a neutral impact on market sentiment.
Positives
- The executive received 3,184 ordinary shares through the vesting of Restricted Stock Units, indicating a successful payout from the company's incentive award plans.
- The RSU vesting demonstrates the company's commitment to its executive compensation structure, aligning management incentives with long-term company performance.
Negatives
- A portion of the vested shares (1,370 ordinary shares) was immediately disposed of to cover tax liabilities, resulting in a reduction of the executive's direct beneficial ownership.
- The disposition of shares, while routine for tax purposes, reduces the executive's direct equity stake in the company.
Risks
- Unvested Restricted Stock Units are subject to forfeiture prior to vesting, in accordance with the terms of the Company's incentive award plans and award agreements.
Future Outlook
The filing indicates ongoing executive compensation through Restricted Stock Units, with future vesting installments scheduled for the remaining unvested portions of the 2022, 2023, 2024, and 2025 RSU grants.
Industry Context
StockSavvy.ai notes that the reported transactions reflect a standard practice in executive compensation within the medical technology and healthcare industry, where Restricted Stock Units are commonly used to incentivize long-term performance and align executive interests with shareholder value. The 'sell-to-cover' mechanism for tax obligations is also a routine aspect of such compensation plans.
Comparison to Industry Standards
- Routine RSU vesting and 'sell-to-cover' transactions are standard executive compensation practices across publicly traded companies, aligning with typical incentive structures designed to retain and motivate key personnel.
- LivaNova's use of multi-year vesting schedules for RSUs is consistent with common corporate governance practices aimed at promoting long-term alignment between executive interests and shareholder value.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Reference to Incentive Plans | The filing references the Company's 2015 Incentive Award Plan, 2022 Incentive Award Plan, and the First Amended and Restated LivaNova PLC 2022 Incentive Award Plan as the frameworks governing the RSU grants. | NA | These plans are established frameworks for executive compensation and do not indicate changes in corporate governance, but rather the ongoing application of existing policies. |
Stakeholder Impact
- Shareholders: The transaction is a routine compensation event and does not directly impact the company's operational performance or strategic direction. It reflects the ongoing cost of executive compensation.
- Employees: The RSU vesting demonstrates the company's commitment to its equity compensation programs, which can be a positive signal for employee retention and motivation.
Next Steps
- Future vesting installments for the remaining Restricted Stock Units granted in 2022, 2023, 2024, and 2025 will occur according to their respective schedules.
Key Dates
| Date | Description |
|---|---|
| 03/30/2022 | Date reporting person was granted RSUs subject to a four-year vesting in equal annual installments. |
| 03/30/2023 | First vesting date for the March 30, 2022 RSU grant; also the date reporting person was granted new RSUs subject to a four-year vesting. |
| 03/30/2024 | First vesting date for the March 30, 2023 RSU grant; also the date reporting person was granted new RSUs subject to a four-year vesting. |
| 03/30/2025 | First vesting date for the March 30, 2024 RSU grant; also the date reporting person was granted new RSUs subject to a three-year vesting. |
| 03/30/2026 | Transaction date for RSU settlement and share disposition; also the first vesting date for the March 30, 2025 RSU grant. |
| 04/01/2026 | Date the Form 4 was signed by the Attorney-in-Fact. |
Recommendation
holdThis Form 4 filing details a routine executive compensation event involving the vesting of Restricted Stock Units (RSUs) and the subsequent sale of shares to cover tax obligations. It does not provide new material information regarding LivaNova PLC's operational performance, strategic direction, or financial health. Therefore, a 'hold' recommendation is appropriate as this transaction does not alter the fundamental investment thesis for the company.
Keywords
LivaNova, LIVN, Form 4, insider transaction, RSU vesting, executive compensation, share ownership, Franco Poletti, restricted stock units, tax withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.